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Proton Therapy Comes into Its Own
(Continued from page 1)
According to Alfred R. Smith,
Ph.D., a professor in the Department of
Radiation Physics at The University of
Texas M. D. Anderson Cancer Center,
the surge in new proton therapy centers
in the United States can be attributed
to three factors: (1) positive results of
clinical studies of proton therapy were
published; (2) proton facilities applied
for and were granted procedure codes
from the American Medical Association, and Medicare and insurance
providers set reimbursement rates,
which enabled proton therapy providers
to be paid; and (3) once it became
evident that such centers would be
able to charge for their services, more
vendors became interested in designing
and building proton therapy facilities.
The economic feasibility of proton
therapy centers coincided with the
development of more precise imaging
and proton treatment delivery methods.
Although the precision of proton beam
therapy has been known for decades,
applications were limited to a few
anatomic sites because of energy and
treatment delivery limitations and the
difficulty in precisely defining the tumor
volume to be treated.
Beginning in the late 1970s,
improved imaging modalities and

improved means of contrast enhancement greatly increased the precision
with which tumors could be visualized.
These improvements, combined with a
better understanding of tumor biology
and the power of sophisticated computers for treatment planning, helped to
justify the cost and effort required to
build clinical proton therapy facilities.
A new $125 million Proton Therapy
Center under construction at M. D.
Anderson (see related article on page 3)
will join 20 proton therapy facilities
worldwide (four in the United States)
that are treating patients. A hospitalbased center is under construction at
the University of Florida at Jacksonville,
and at least five other centers are in
the initial planning stages.
“So it’s a very exciting period for
proton therapy. Those of us who have
spent most of our lives in particle
therapy are of course very happy
about this,” said Dr. Smith.
The advantages of protons
The main advantage of protons over
photons has to do with the way their
energy is released. Much of the total
dose of a photon is deposited before it
gets to a tumor, and a photon beam
continues to deposit energy after passing

The proton therapy planning system development team discusses a sample treatment
plan for a patient with prostate cancer. Sitting from left to right are Robin Famiglietti,
an administrative director in the Department of Radiation Physics; Dr. Shiao Woo,
a professor in the Department of Radiation Oncology; Dr. Radhe Mohan, professor
and chair of the Department of Radiation Physics; and Beverly Riley, a medical
dosimetrist in the Department of Radiation Oncology. Standing from left to right are
Stephen Bilton, a clinical supervisor in the Department of Radiation Physics, and
Dr. Xiaodong Zhang, an instructor in the Department of Radiation Physics.
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through the tumor. Protons, on the
other hand, deposit a much lower dose
before arriving at the tumor and can
be stopped immediately after exiting
the tumor. This results in a much lower
dose to normal surrounding tissues while
allowing for the delivery of a higher
treatment dose to the tumor with fewer
side effects. Higher doses delivered to
the tumor will result in higher rates of
local control and disease-free survival
in many tumor sites.
“It is our strong belief that most
tumors that are treated with x-rays can
receive a more localized dose distribution with protons,” Dr. Smith said. “In
those cases where local control is quite
good with photons, you can decrease
late effects using protons.”
Improving proton therapy
In standard proton therapy, a proton
beam entering the treatment delivery
nozzle is scattered into a broad, uniform
beam and shaped to conform to the
tumor. The process of scattering the
protons generates neutrons, which could
cause late effects, including new tumors
years after treatment. These effects are
comparable to those caused by radiation
therapy using photons, which can be
cause for concern. Using computerized
treatment planning methods, a team of
researchers led by Radhe Mohan, Ph.D.,
professor and chair of the Department of
Radiation Physics, is applying intensitymodulated delivery techniques to proton
therapy. This method of treatment
delivery will use a pencil-beam scanning
nozzle that was designed especially for
the M. D. Anderson facility.
With intensity-modulated proton
therapy, or IMPT, a single, narrow
proton beam about a centimeter in
diameter is swept across the tumor
from multiple directions, depositing
the radiation dose, mostly near the end
of the beam’s range. The energy of the
proton beam can be changed at any
time to penetrate the tumor at varying
depths. The technique is also known as
pencil-beam scanning, but Dr. Mohan
describes the process as using a paintbrush to apply proton energy to the
tumor. “Using magnets, we make it
sweep across the tumor,” he said, “but

Proton Therapy
Comes into Its Own

Treating Patients with Cancer

(Continued from page 3)
by David Galloway
Defining proton therapy’s potential
All patients treated in M. D.
Anderson’s new Proton Therapy Center
will be entered into protocols. In
general, these studies will help clinicians
understand how to use proton therapy
optimally and quantify the improvements in clinical outcomes that can be
achieved with proton therapy. A specific
question that the researchers will try to
answer is whether proton therapy can be
delivered in fewer fractions at higher
doses per fraction. Completing treatments during a shorter period of time by
delivering fewer fractions would allow
for minimal tumor growth, be less
expensive, and enable the center to treat
more patients. However, clinical studies
are needed to determine how much
treatments can be shortened without
sacrificing efficacy or safety.
Because, on average, protons deliver
half the dose to normal tissues that
photons deliver, it may be possible to
give a more intense regimen of chemotherapy in conjunction with proton
therapy, with fewer side effects than
can be expected with chemotherapy
combined with photon therapy.
Another question about proton
therapy that researchers hope to answer
has to do with the biological effect of
protons. Owing in part to the ability of
protons to kill tumor cells in the absence
of oxygen, proton therapy produces an
elevated biological response in tumor
cells. In general, this effect is believed to
be about 10% greater than that of
photon therapy, but the response appears
to vary depending on the type of tumor,
the dose, and other factors.
“I think there can be a number of
studies done to more clearly define the
tissue-, organ-, and tumor-specific
biological response. Once we do that, it
will enable us to give even better
treatment. Instead of using a generalized
factor for all tissues and all tumors, we
will be able to optimize the treatment
even more,” Dr. Smith said. ●
FOR MORE INFORMATION, contact Dr. Smith
at (713) 563-1519 or Dr. Mohan at (713)
563-2505.
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W

hen a cancer is
diagnosed, it is
common for all
attention to be
focused on the tumor, and
everything else—including the
patient’s other medical conditions—tends to fall by the
wayside. But if the patient is
cured of cancer and dies of
a heart attack the following
week, the treatment cannot
be considered a success.

“It’s important to keep comorbid
conditions in mind for the sake of the
entire patient and not just focus on
the cancer,” said Ellen F. Manzullo,
M.D., F.A.C.P., an associate professor
in the Department of General Internal
Medicine, Ambulatory Treatment, and
Emergency Care at The University of
Texas M. D. Anderson Cancer Center,
“because the patient can do extremely
well as far as their cancer is concerned
but subsequently die of coronary artery
disease or stroke.”
Some comorbid conditions exist
before the cancer, and others develop
later on. “As survival increases with
cancer, we are going to run into patients
who have had the time to develop other
problems that might not be related to
the cancer,” said Joseph Swafford, M.D.,
an associate professor in the Department
of Cardiology at M. D. Anderson. “And
when they come back for surveillance,
we end up picking up on some of those
problems.”
Comorbidities affect
cancer treatment
A patient’s other medical conditions
can alter the course of cancer treatment.
For example, for a patient with a single
lung tumor, surgery would normally
be the first treatment considered.
However, if that patient has severe
chronic obstructive pulmonary disease

or coronary artery disease, surgery
might prove more deadly than the lung
cancer.
As many as 25% of patients whose
lung tumors would otherwise be considered resectable cannot undergo surgery
because of heart or lung problems, said
Ritsuko Komaki, M.D., F.A.C.R., a
professor in the Department of Radiation Oncology at M. D. Anderson.
“We have to treat those patients with
radiation therapy, alone or with chemotherapy,” she said. At the same time,
internal medicine specialists administer
medications or use physical therapy to
improve the patient’s lung function or
cardiac function so that surgery will be
an option later.
Of course, there are emergency
situations in which there is no choice
but to take a patient to surgery. But in
most other cases, internists have time
to evaluate the patient before surgery
and develop strategies to maximize the
safety and success of surgical procedures,
Dr. Manzullo said.
A patient’s comorbid conditions
can also interfere with chemotherapy
and radiation therapy. In lung cancer,
“usually, we go with concurrent treatment, chemotherapy and radiation
therapy,” Dr. Komaki said. “The chemotherapy will promote the radiation
effects to kill more cancer cells. But it
also sensitizes the normal cells, and
sensitive normal cells will be killed by
concurrent chemotherapy and radiation
therapy.” A patient with compromised
lung function or cardiac function might
not be able to tolerate that damage, so
researchers are searching for the optimal
sequential treatment.
Other conditions affecting cancer
treatment include hypertension,
diabetes, kidney problems, congestive
heart failure, and Alzheimer’s disease.
Diabetes, for example, complicates
cancer treatment by interfering with a
patient’s healing processes. Concurrent
chemotherapy and radiation therapy,
commonly used in the treatment of
many cancers, lowers a patient’s blood
count, especially the neutrophils.
Patients with diabetes are then left
especially vulnerable to infections.

Requires Looking Beyond the Tumor

Dr. Ellen F. Manzullo, an associate professor in the Department of General Internal
Medicine, Ambulatory Treatment, and Emergency Care, consults with patient
in the Ambulatory Treatment Center.
Although the connection might not
seem obvious, Alzheimer’s disease and
other cognitive disorders can alter the
treatment of lung cancer. In the case of
nonmetastatic small cell lung cancer
(SCLC), the usual treatment includes
prophylactic brain irradiation to
counteract that disease’s propensity to
spread to the brain. However, prophylactic brain irradiation is contraindicated if the patient’s mental function
is already compromised by Alzheimer’s
disease, chronic alcoholic brain syndrome, or other mental disorders.

“Sometimes, these patients have
medical conditions that they’re not
even aware of,” Dr. Manzullo said.
“They come here for their cancer
treatment, and then we discover that
they have other medical conditions
that need to be treated.”
Identifying and treating comorbid
conditions can significantly affect
a patient’s overall prognosis. “Sometimes, it can be just as important as
the cancer itself as far as determining
how well the patient will do,” Dr.
Manzullo said.

Cancer and treatment
affect comorbidities
Other comorbid conditions are
caused by cancer or its treatment.
SCLC, for example, produces a hormone
that can lead to Eaton-Lambert syndrome, leaving a patient with severe
muscle weakness. If the SCLC is
resected or otherwise successfully
treated, the patient’s muscle strength
will return.
Sometimes, a comorbid condition
caused by a cancer will appear before
the malignancy is found. Dr. Komaki
told of a 70-year-old woman undergoing
treatment for SCLC whose cancer was
discovered in an attempt to diagnose a
sudden mental deterioration. “She was
totally confused, and so she was taken
to the emergency room, where they did
an MRI [magnetic resonance imaging],
and there was no cancer or any other
abnormality. But her sodium level was
very, very low. That was caused by
small cell lung cancer, or paraneoplastic
syndrome. Now, after two weeks of
treatment, her sodium level is up, and
she walked to the park and enjoyed the
weekend. Her cancer has almost gone,
and the cancer-related muscle weakness
and the mental confusion have disappeared.”
Some common chemotherapeutic
agents—paclitaxel, doxorubicin, and
trastuzumab, for example—can trigger
hypertension or problems with the
heart, such as arrhythmias, congestive
heart failure, or bradycardia. “There
are some, like 5-FU [fluorouracil] and
Xeloda [capecitabine], that can cause
chest pains, resulting from spasms of
the arteries that go to the heart,”
Dr. Swafford said. Many patients on
chemotherapy become anemic, and
that can trigger further cardiac complications. Studies now are investigating
whether drugs such as angiotensinconverting enzyme inhibitors and
beta-blockers, commonly used to treat
congestive heart failure, can be used
to prevent that condition in patients
undergoing chemotherapy.
Other agents affect the kidneys,
sometimes to the point of requiring
(Continued on page 6)
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Looking Beyond the Tumor
(Continued from page 5)
dialysis. In addition, because many
patients on chemotherapy are
immunocompromised, pulmonary
infections are quite common.
Another treatment-related problem
is esophagitis, which is caused by
radiation therapy to the chest. “It is
very difficult to avoid normal tissue
damage right around the tumor,” Dr.
Komaki said. “And the esophagus is
very sensitive to radiation. Esophagitis
makes it very painful to swallow food,
so we do everything possible to minimize that complication.” The best way
to minimize toxicity from radiation
therapy is to limit the volume of tissue
irradiated. Advances in imaging and
radiation therapy delivery such as
immobilization and respiration gating
over the past few years have made it
possible to irradiate less normal tissue
while still hitting the tumor, and the
hope is that fewer radiation-related
complications will be seen.
Clinicians are making many efforts
to limit the side effects of cancer
treatment, including using more focused
radiation beams and cytoprotective
agents to give normal cells a fighting
chance against chemotherapy and
radiation therapy. One such cytoprotector is nothing new. Amifostine
(WR-2721), which was synthesized
at the Walter Reed Army Institute of
Research during the Cold War years to
protect soldiers from radioactive fallout,
is activated by alkaline phosphatase,

Identifying and
treating comorbid
conditions “can be just
as important as the
cancer itself as far as
determining how well
the patient will do.”
– Ellen F. Manzullo, M.D., F.A.C.P.,
associate professor, Department of
General Internal Medicine, Ambulatory Treatment, and Emergency Care
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an enzyme found in the membranes
of normal cells but not (or at greatly
reduced levels) in the membranes of
tumor cells. Clinical trials have shown
that it does protect normal cells, but not
tumor cells, during concurrent chemotherapy and radiation therapy.
Managing comorbid conditions
on an outpatient basis
Most patients treated at M. D.
Anderson are seen as outpatients, and
while that arrangement has many
benefits for patients, it affords healthcare providers fewer opportunities to
assess the patient’s overall health.
“They usually eat what they want
and so on, so we don’t have much
control,” Dr. Komaki said. “But I think
they should be treated as outpatients.
Cancer patients should function as
normally as they can. We should not
confine them in a hospital, the way they
do in some other countries. When they
are outpatients, their spirit is better, and
they can be more active, which is very
important to maintain their appetite
and weight and to reduce the chances
of muscle weakness, osteoporosis, deep
vein thrombosis, depression, et cetera.”
At least one therapy that is normally
reserved for inpatients can now be given
on an outpatient basis, in the right
setting. “An example of that is the use
of Natrecor [nesiritide] for congestive
heart failure,” Dr. Swafford said. “We’ve
worked out with the ATC [Ambulatory
Treatment Center] that patients can go
there and get their Natrecor for six to
eight hours and see if that will help
decrease their need for admissions to
the hospital.”
On the other hand, if outpatients
experience side effects when they are
not at the treatment center, “we have to
make sure they come to the emergency
room very quickly so they don’t suffer
and die of complications like sepsis,”
Dr. Komaki said. The key to that, she
said, is making sure patients are well
informed. ●
FOR MORE INFORMATION, contact
Dr. Manzullo at (713) 745-4516,
Dr. Swafford at (713) 792-7612, or
Dr. Komaki at (713) 563-2300.

Conference Offered
on Comorbid
Conditions

T

o give health-care providers a
closer look at many comorbid
conditions, The University
of Texas M. D. Anderson Cancer
Center is offering a conference,
“Internal Medicine and the
Cancer Patient,” September
10 – 11, 2004, in the Houston
Marriott Medical Center in
Houston, Texas. Ellen F. Manzullo,
M.D., F.A.C.P., an associate professor
in the Department of General
Internal Medicine, Ambulatory
Treatment, and Emergency Care,
will chair the conference.
The goal of the conference is to
educate participants to recognize,
diagnose, and treat the wide spectrum of comorbid conditions seen
in patients with cancer. Participants
also will be informed of the unique
aspects of some of these medical
conditions in cancer patients.
Presentations scheduled for the
conference include the following:
• Noninvasive Diagnosis of Cardiac
Disease in Cancer Patients
• Rheumatology in the Cancer
Patient
• Cancer-Related Fatigue
• Osteoporosis and Other Bone
Diseases in Cancer Patients
• Evaluation of Thyroid Nodules
• Psychiatric Issues in Cancer
Patients
• Catheter-Related Infections
• Thrombosis/Bleeding in Cancer
Patients
• 10 Years of Experience: The
Ethics Consult Service at M. D.
Anderson
• When the Patient has a Finding
Suspicious of Cancer … What to
Do?
• Diabetes in the Cancer Patient
• Hypertension in the Cancer
Patient. ●
FOR MORE INFORMATION, call the Office
of Continuing Medical Education/
Conference Services at (713) 792-2222.

